Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-08-29

Clinical Trial Update: A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3) [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of suvorexant in participants with primary insomnia completed; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Suvorexant (suvorexant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Insomnia | Phase 3 | Status: COMPLETED | Results posted: 2014-08-29